Journal Publication

Assay validates lumateperone PK profile in Chinese subjects for the first time

An LC-MS/MS method quantifying lumateperone and its four active metabolites reported the drug's first full pharmacokinetic profile in a Chinese population.

By AppliedXLJuly 15, 2026

Executive Summary

A newly validated plasma assay measured lumateperone alongside its four active metabolites simultaneously, and researchers used it to characterize how the drug behaves in the body in a population where this had not previously been documented.
Because lumateperone's clinical effects depend on both the parent drug and its metabolites, a method that reliably captures all five compounds at once gives a cleaner basis for future pharmacokinetic and bridging work in this population.
Exposure to the drug and its metabolites was lower and slower to peak when the drug was taken with food, a finding that speaks directly to dosing guidance rather than to safety or efficacy.

The stake

Lumateperone is an antipsychotic that is metabolized into four active compounds, IC200131, IC200161, IC200565, and IC201308, that are closely tied to its clinical efficacy and safety. Because those metabolites contribute to the drug's clinical activity, measuring all five compounds accurately and simultaneously in plasma is a prerequisite for any pharmacokinetic study that aims to characterize how the drug behaves in a given population. A

How it was done

The study developed and validated a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to quantify lumateperone and its four metabolites in human plasma, using an alkaline mobile phase and a Zorbax Extend-C18 column with two-step gradient elution to resolve peak tailing and carryover issues. Calibration ranges spanned 0.100 to 80.0 ng/mL for lumateperone and IC200131, 0.0400 to 32.0 ng/mL for IC200161 and IC201308, and 0.150 to 30.0 ng/mL for IC200565. The validated method was then applied to a pharmacokinetic study of lumateperone tosylate capsules registered with the Chinese Clinical Trial Registry under identifier CTR20242699. A

The result

Under fasting conditions, lumateperone showed a mean peak plasma concentration (Cmax) of 30.6 ng/mL and a total drug exposure (AUC0-t) of 72.8 hour times ng/mL. Food intake delayed absorption and lowered Cmax across lumateperone and all four metabolites, a standard food-effect finding that informs how the drug should be dosed relative to meals rather than a safety or efficacy signal. A

What it establishes

The authors describe this as the first comprehensive pharmacokinetic profile of lumateperone and its four active metabolites reported in Chinese subjects, providing values that can serve as a reference point for future pharmacokinetic and bridging work in this population. The contribution is methodological and descriptive: a validated bioanalytical tool paired with exposure data, not a clinical efficacy or safety readout. A

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.